Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
用于儿科药物掩味和控释的工程微粒
基本信息
- 批准号:8396082
- 负责人:
- 金额:$ 21.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2013-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAgeBiocompatible Coated MaterialsBiological AssayCaliberChairpersonCharacteristicsChildChildhoodCitiesClinicalDevelopmentDiseaseDosage FormsDoseDrug Delivery SystemsDrug FormulationsDrug IndustryEncapsulatedEngineeringEnsureEvaluationFeasibility StudiesFlavoringFoundationsGoalsHospitalsIncentivesIndustryKansasMasksMedical ResearchMedication ErrorsMissouriModelingOral cavityParticle SizePatientsPerformancePharmaceutical PreparationsPharmacologic SubstancePharmacologyPhasePhysician ExecutivesPositioning AttributePrincipal InvestigatorProductionPropertyProteinsProviderResearchShapesSolutionsSurfaceTabletsTaste PerceptionTechniquesTechnologyTestingThickTimeTitrationsUniversitiesWorkbasecapsulecompliance behaviorcontrolled releasedesigndosagedrug developmenteffective therapyexperienceflexibilityimprovedlarge scale productionmeetingsnew technologyparticlepediatric pharmacologyresearch clinical testingsegregationsuccesstechnology developmentuser-friendly
项目摘要
DESCRIPTION (provided by applicant): Pediatric drug development presents many unique challenges in the effective treatment of diseases in children, from adequate dosing information and pediatric-specific testing to palatable flavor profiles and effective delivery formats. A novel
technology that masks bitter drug flavors while providing flexibility in dose design and format would enable formulation of existing adult pharmaceutical products into medications specially designed for pediatric patients. Our proposed strategy uses Precision Particle Fabrication (PPF) to develop pediatric drug-loaded microparticles that mask bitter flavors and allow for flexible dosing and formats. The central advantage of PPF technology lies in its precise control of particle size, shape, material, and release rates. Our long-term goal is to adapt this flexible, user-friendly, inexpensive technology to create a platform for microencapsulating unpalatable pediatric active pharmaceutical ingredients (API's). We hypothesize that the uniform, precisely engineered microparticles produced by PPF will create effectively taste- masked formulations for pediatric drugs while also allowing for the swift and controlled release of the active agents under digestive conditions. We further hypothesize that this robust microparticle strategy will allow for accurate, flexible dosing and adaptation to multiple drug delivery formats. Our research team will develop and characterize model bitter API-containing microparticles with precisely controlled physicochemical features that are designed to meet palatability standards (Aim 1). We will then optimize the release characteristics and taste-masking performance of these model microparticles (Aim 2). The result will be model drug-loaded microparticles that meet palatability standards based on particle size, homogeneity, and drug surface concentration and that can be tailored for desired release profiles under digestive conditions. After establishing the feasibility of precisely engineering these microparticles, Phase II will focus on the clinical evaluation of organoleptic properties of taste and mouth feel as well as demonstration of dosing accuracy, titration, and format flexibility. This PPF-based encapsulation strategy addresses issues of palatability, dosage accuracy, and format flexibility in pediatric drugs, while improving upon existing encapsulation techniques that are costly and time-consuming and produce poorly controlled, heterogeneous batches of microparticles. In adition, this PF technology is highly adaptable to multiple drugs and matrix/coating materials as well as large-scale production. The result will be an inexpensive, highly flexible pediatric platform for creating palatable, age-appropriate, and accurate dosage forms, leading to safer pediatric formulations and improved patient compliance.
PUBLIC HEALTH RELEVANCE: Inadequate pediatric pharmaceutical formulations impair effective treatment of diseases in children due to poor compliance, ad hoc formulations, and dangerous medication errors. At the foundation of the problem are palatability, accurate dosing, and age-appropriate dosage format challenges. Development of a user-friendly, inexpensive development platform for pediatric reformulation of existing adult drug products to administer taste-masked active pharmaceutical ingredients (APIs) with controlled release rates is needed. Using model bitter APIs, this project aims to test the feasibility of Precision Particle Fabricatio technology to produce palatable, age-appropriate, and accurate doses as a means to safer pediatric medications and better compliance.
描述(由申请人提供):儿科药物开发在有效治疗儿童疾病方面提出了许多独特的挑战,从充分的剂量信息和儿科特异性测试到美味的风味特征和有效的递送形式。一本小说
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cory Berkland其他文献
Cory Berkland的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cory Berkland', 18)}}的其他基金
Preparing BBI-001 as an oral, non-absorbed iron chelator for prevention of iron overload
将 BBI-001 制备为口服非吸收铁螯合剂,用于预防铁过载
- 批准号:
10258539 - 财政年份:2021
- 资助金额:
$ 21.6万 - 项目类别:
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
用于 Tran 的精密颗粒制造负载倍他米松的微球
- 批准号:
8396087 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8433328 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8239401 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Targeted nanoscale antigen arrays for treating autoimmune diseases
用于治疗自身免疫性疾病的靶向纳米级抗原阵列
- 批准号:
8513574 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8804184 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8607930 - 财政年份:2012
- 资助金额:
$ 21.6万 - 项目类别:
Multi-day Pain Management Therapy with Novel Injectable Formulation
采用新型注射制剂的多日疼痛管理疗法
- 批准号:
8198342 - 财政年份:2011
- 资助金额:
$ 21.6万 - 项目类别:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
扩展精密粒子制造技术以实现广泛控制
- 批准号:
7908631 - 财政年份:2010
- 资助金额:
$ 21.6万 - 项目类别:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
扩展精密粒子制造技术以实现广泛控制
- 批准号:
8089561 - 财政年份:2010
- 资助金额:
$ 21.6万 - 项目类别:
相似海外基金
Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
制定年轻人介导的干预措施,以增加农村符合筛查年龄的成年人的结直肠癌筛查
- 批准号:
10653464 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Doctoral Dissertation Research: Estimating adult age-at-death from the pelvis
博士论文研究:从骨盆估算成人死亡年龄
- 批准号:
2316108 - 财政年份:2023
- 资助金额:
$ 21.6万 - 项目类别:
Standard Grant
Determining age dependent factors driving COVID-19 disease severity using experimental human paediatric and adult models of SARS-CoV-2 infection
使用 SARS-CoV-2 感染的实验性人类儿童和成人模型确定导致 COVID-19 疾病严重程度的年龄依赖因素
- 批准号:
BB/V006738/1 - 财政年份:2020
- 资助金额:
$ 21.6万 - 项目类别:
Research Grant
Transplantation of Adult, Tissue-Specific RPE Stem Cells for Non-exudative Age-related macular degeneration (AMD)
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 (AMD)
- 批准号:
10294664 - 财政年份:2020
- 资助金额:
$ 21.6万 - 项目类别:
Sex differences in the effect of age on episodic memory-related brain function across the adult lifespan
年龄对成人一生中情景记忆相关脑功能影响的性别差异
- 批准号:
422882 - 财政年份:2019
- 资助金额:
$ 21.6万 - 项目类别:
Operating Grants
Modelling Age- and Sex-related Changes in Gait Coordination Strategies in a Healthy Adult Population Using Principal Component Analysis
使用主成分分析对健康成年人群步态协调策略中与年龄和性别相关的变化进行建模
- 批准号:
430871 - 财政年份:2019
- 资助金额:
$ 21.6万 - 项目类别:
Studentship Programs
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 AMD
- 批准号:
9811094 - 财政年份:2019
- 资助金额:
$ 21.6万 - 项目类别:
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 21.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Doctoral Dissertation Research: Literacy Effects on Language Acquisition and Sentence Processing in Adult L1 and School-Age Heritage Speakers of Spanish
博士论文研究:识字对西班牙语成人母语和学龄传统使用者语言习得和句子处理的影响
- 批准号:
1823881 - 财政年份:2018
- 资助金额:
$ 21.6万 - 项目类别:
Standard Grant
Adult Age-differences in Auditory Selective Attention: The Interplay of Norepinephrine and Rhythmic Neural Activity
成人听觉选择性注意的年龄差异:去甲肾上腺素与节律神经活动的相互作用
- 批准号:
369385245 - 财政年份:2017
- 资助金额:
$ 21.6万 - 项目类别:
Research Grants














{{item.name}}会员




